ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
HighCape Capital Acquisition Corporation

HighCape Capital Acquisition Corporation (CAPA)

10.68
0.00
(0.00%)
Closed 06 January 8:00AM
0.00
0.00
(0.00%)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
10.68
Bid
10.67
Offer
10.75
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
10.68
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
121,791,000
Dividend Yield
-
PE Ratio
-5.43
Earnings Per Share (EPS)
-0.79
Revenue
1.08M
Net Profit
-95.96M

About HighCape Capital Acquisition Corporation

HighCape Capital Acquisition Corp is a blank check company. HighCape Capital Acquisition Corp is a blank check company.

Sector
Meas & Controlling Dev, Nec
Industry
Meas & Controlling Dev, Nec
Headquarters
Wilmington, Delaware, USA
Founded
-

CAPA Latest News

Quantum-Si Announces Expansion of Early Access Program for the Platinum™ Single Molecule Protein Sequencing Platform

Quantum-Si Incorporated (NASDAQ: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life science tools company commercializing a unique protein sequencing platform, announced today that they have...

Quantum-Si Incorporated to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si” or the “Company”), a company pioneering next-generation semiconductor chip-based proteomics, today announced its participation in the Cantor...

Quantum-Si Reports Second Quarter 2021 Financial Results

Quantum-Si Solidifies Financial Strength and Continues Systematic Commercialization Strategy Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si” or the “Company”), a company pioneering...

Quantum-Si to Report Second Quarter 2021 Financial Results on August 16, 2021

Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, today announced that it has rescheduled its conference call to report second quarter 2021...

Quantum-Si Signs Lease for Product Development and Operations Facility in San Diego Biotechnology Hub

Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, announced today that it has entered into a lease agreement with Phase 3 Real Estate Partners...

Quantum-Si, Revolutionizing Proteomics, Closes Bus. Combination & Will Begin Trading Under the Ticker “QSI” on the Nasdaq...

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSi” or “the Company”), a company pioneering next-generation semiconductor chip-based proteomics, today announced that it has completed its...

HighCape Capital Acquisition Corp. Reminds Stockholders to Vote in Favor of the Business Combination with Quantum-Si Incorpor...

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- HighCape Capital Acquisition Corp. (Nasdaq: CAPA) (“HighCape”), a special purpose acquisition company sponsored by leading healthcare growth equity...

HighCape Capital Acquisition Corp. Reminds Stockholders to Vote in Favor of the Business Combination with Quantum-Si Incorpor...

NEW YORK, May 27, 2021 (GLOBE NEWSWIRE) -- HighCape Capital Acquisition Corp. (Nasdaq: CAPA) (“HighCape”), a special purpose acquisition company sponsored by leading healthcare growth equity...

Quantum-Si Strengthens Board of Directors With Two Key Appointments

Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, announced today the appointment of Marijn Dekkers, Ph.D. and Ruth Fattori to its Board of...

Quantum-Si Appoints Dr. Michael Mina as Chief Medical Advisor

Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, announced today the appointment of Michael Mina, M.D., Ph.D., Assistant Professor of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

CAPA - Frequently Asked Questions (FAQ)

What is the current HighCape Capital Acquisi... share price?
The current share price of HighCape Capital Acquisi... is US$ 10.68
How many HighCape Capital Acquisi... shares are in issue?
HighCape Capital Acquisi... has 121,791,000 shares in issue
What is the market cap of HighCape Capital Acquisi...?
The market capitalisation of HighCape Capital Acquisi... is USD 1.3B
What is the 1 year trading range for HighCape Capital Acquisi... share price?
HighCape Capital Acquisi... has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of HighCape Capital Acquisi...?
The price to earnings ratio of HighCape Capital Acquisi... is -5.43
What is the cash to sales ratio of HighCape Capital Acquisi...?
The cash to sales ratio of HighCape Capital Acquisi... is 480.9
What is the reporting currency for HighCape Capital Acquisi...?
HighCape Capital Acquisi... reports financial results in USD
What is the latest annual turnover for HighCape Capital Acquisi...?
The latest annual turnover of HighCape Capital Acquisi... is USD 1.08M
What is the latest annual profit for HighCape Capital Acquisi...?
The latest annual profit of HighCape Capital Acquisi... is USD -95.96M
What is the registered address of HighCape Capital Acquisi...?
The registered address for HighCape Capital Acquisi... is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the HighCape Capital Acquisi... website address?
The website address for HighCape Capital Acquisi... is www.quantum-si.com
Which industry sector does HighCape Capital Acquisi... operate in?
HighCape Capital Acquisi... operates in the MEAS & CONTROLLING DEV, NEC sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FCUVFocus Universal Inc
US$ 0.9499
(174.93%)
260.93M
NITON2OFF Inc
US$ 2.6306
(145.85%)
358.28M
CRNCCerence Inc
US$ 19.33
(143.76%)
161.8M
KITTNauticus Robotics Inc
US$ 3.8249
(140.56%)
104.8M
ACONAclarion Inc
US$ 0.2984
(110.14%)
305.64M
HWHHWH International Inc
US$ 0.4621
(-28.80%)
7.08M
SMSTDefiance Daily Target 2x Short MSTR ETF
US$ 5.69
(-26.30%)
24.62M
RAINRain Enhancement Technologies Holdco Inc
US$ 5.59
(-23.42%)
155.16k
PTLEPTL Ltd
US$ 9.35
(-23.30%)
967.95k
NXUNXU Inc
US$ 0.725868
(-22.78%)
7.4M
NITON2OFF Inc
US$ 2.6306
(145.85%)
358.28M
TGLTreasure Global Inc
US$ 0.382
(101.58%)
337.5M
ACONAclarion Inc
US$ 0.2984
(110.14%)
305.64M
FCUVFocus Universal Inc
US$ 0.9499
(174.93%)
260.93M
NVDANVIDIA Corporation
US$ 144.47
(4.45%)
230.01M

CAPA Discussion

View Posts
Quacker Quacker 3 years ago
Where is my mirror Television? :)
👍️0
TallTrader TallTrader 4 years ago
Investor presentation...

https://assets.website-files.com/5e3ba888b619ec2d758ec4cb/602e47a1c5496f3a68af7fed_Quantum-Si%20PIPE%20Master%20Final%20Feb%2018.pdf
👍️0
TallTrader TallTrader 4 years ago
CAPA and Quantum-Si, Pioneer in Chip-Based Proteomics

NEW YORK and GUILFORD, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (“Quantum-Si”, "QSi" or the "Company"), a pioneer in next generation semiconductor chip-based proteomics, and HighCape Capital Acquisition Corp. (Nasdaq: CAPA) (“HighCape”), a special purpose acquisition company sponsored by HighCape Capital LP, announced today that they have entered into a definitive business combination agreement. Upon completion of the transaction, the combined company's Class A common stock is expected to be traded on The Nasdaq Stock Market (“Nasdaq”) under the symbol "QSI".

Company Overview
Quantum-Si has created the first next-generation protein sequencing platform with the goal of revolutionizing the growing field of proteomics. Our unique semiconductor chip has the power to decode the molecules of life, starting with proteins, and holds the potential to expand the scale of the genomics and proteomics market beyond that of next-generation DNA sequencing.

QSi’s end-to-end solution, including Carbon and Platinum, which is on track to launch commercially in 2022 for research use, has the potential to significantly disrupt an existing addressable $21 billion market of pharmaceutical, academic research and drug discovery. The platform also may enable new diagnostic applications in healthcare.

https://www.globenewswire.com/news-release/2021/02/18/2177804/0/en/Quantum-Si-a-Pioneer-in-Semiconductor-Chip-Based-Proteomics-to-Combine-with-HighCape-Capital-Acquisition-Corp.html
👍️0

Your Recent History

Delayed Upgrade Clock